November 19, 2018 05:50 AM EST

Undeterred by exec exodus, Immunocore nabs $100M cash to co-develop preclinical asset with Roche

ENDPOINTS

Despite its recent executive exodus, cancer biotech Immunocore’s appetite for partnership deals remains relentless. The Oxford University spinout is now set to test a preclinical …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Undeterred by exec exodus, Immunocore nabs $100M cash to co-develop preclinical asset with Roche

ENDPOINTS

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Un­de­terred by ex­ec ex­o­dus, Im­muno­core nabs $100M cash to co-de­vel­op pre­clin­i­cal as­set with Roche

ENDPOINTS

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Undeterred by exec exodus, Immunocore nabs $100M cash to co-develop preclinical asset with Roche

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival